Protein L is known as a “superantigen” because it can bind antibodies in unusual ways
KER-065 is a novel ligand trap comprised of a modified ligand-binding domain derived from activin receptor type IIA and activin receptor type IIB
The company has improved access to quality healthcare for seniors across both urban and rural areas
The facility will be positioned as a Centre of Excellence for tertiary care services
The patient had been battling DFSP for over eight years, enduring multiple recurrences despite three previous surgeries
Projects 5X revenue growth by 2028, accelerates global market leadership and paves the way for IPO
Inclacumab was generally well tolerated in THRIVE-131
Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo
Subscribe To Our Newsletter & Stay Updated